

Kausik K Ray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5825164/publications.pdf>

Version: 2024-02-01

214
papers

44,392
citations

6606

79
h-index

2125

203
g-index

217
all docs

217
docs citations

217
times ranked

30775
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
2	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
3	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2013, 369, 1317-1326.	13.9	3,017
4	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
5	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292
6	Major Lipids, Apolipoproteins, and Risk of Vascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1993.	3.8	2,205
7	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet, The</i> , 2010, 375, 735-742.	6.3	2,064
8	Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009, 373, 1765-1772.	6.3	1,234
9	Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2556.	3.8	1,197
10	Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
11	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	1.0	993
12	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	1.0	835
13	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	1.0	776
14	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2020, 382, 1507-1519.	13.9	758
15	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2017, 376, 1430-1440.	13.9	735
16	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
17	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	1.0	644
18	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	6.3	562

#	ARTICLE	IF	CITATIONS
19	Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2008, 51, 724-730.	1.2	534
20	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. <i>New England Journal of Medicine</i> , 2019, 380, 1022-1032.	13.9	529
21	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	5.5	473
22	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 382, 1520-1530.	13.9	463
23	Association of Triglyceride-Lowering LPL Variants and LDL-Câ€“Lowering LDLR Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	3.8	460
24	Statins and All-Cause Mortality in High-Risk Primary Prevention. <i>Archives of Internal Medicine</i> , 2010, 170, 1024.	4.3	385
25	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1279-1289.	0.8	369
26	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 850-861.	5.5	329
27	Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1405-1410.	1.2	313
28	Position paper Statin intolerance â€“ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
29	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1411-1416.	1.2	306
30	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1742-1759.	1.6	301
31	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	1.0	270
32	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
33	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	3.8	247
34	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
35	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
36	Mendelian Randomization Study of ACLY and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1033-1042.	13.9	216

#	ARTICLE	IF	CITATIONS
37	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
38	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
39	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2017, 40, 69-76.	4.3	205
40	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. <i>Circulation</i> , 2016, 134, 1419-1429.	1.6	183
41	Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 588-597.	5.5	175
42	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	1.0	171
43	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	2.3	169
44	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	3.0	169
45	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.4	163
46	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	1.2	162
47	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , 2019, 394, 1169-1180.	6.3	155
48	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018, 41, 1281-1288.	0.7	151
49	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.4	148
50	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891.	1.6	144
51	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	3.8	144
52	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016, 253, 194-208.	0.4	142
53	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet</i> , 2021, 398, 1713-1725.	6.3	142
54	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 433-442.	0.4	139

#	ARTICLE	IF	CITATIONS
55	The impact of statin therapy on plasma levels of von Willebrand factor antigen. <i>Thrombosis and Haemostasis</i> , 2016, 115, 520-532.	1.8	138
56	Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 424-430.	1.1	136
57	Effect of Serial Infusions of CER-001, a Pre- β^2 High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. <i>JAMA Cardiology</i> , 2018, 3, 815.	3.0	135
58	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 1124.	3.0	128
59	Association between statin use and plasma D-dimer levels. <i>Thrombosis and Haemostasis</i> , 2015, 114, 546-557.	1.8	127
60	Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins. <i>Circulation</i> , 2018, 138, 1304-1316.	1.6	127
61	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , 2018, 138, 770-781.	1.6	126
62	Long-Term Prognostic Value of Neopterin. <i>Circulation</i> , 2007, 115, 3071-3078.	1.6	125
63	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1182-1193.	1.2	122
64	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
65	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	1.0	117
66	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 50-67.	5.5	114
67	Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1417-1424.	1.2	113
68	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. <i>European Heart Journal</i> , 2018, 39, 2540-2545.	1.0	113
69	Reductions in Atherogenic Lipids and Major Cardiovascular Events. <i>Circulation</i> , 2016, 134, 1931-1943.	1.6	110
70	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DIABETES INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1781-1792.	2.2	105
71	Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels. <i>JAMA Cardiology</i> , 2019, 4, 1067.	3.0	104
72	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104

#	ARTICLE	IF	CITATIONS
73	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , 2018, 15, 261-272.	6.1	101
74	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. <i>Mayo Clinic Proceedings</i> , 2020, 95, 77-89.	1.4	97
75	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 109-115.	1.0	92
76	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	1.0	92
77	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
78	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. <i>Atherosclerosis</i> , 2015, 241, 409-418.	0.4	87
79	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <i>Nature Reviews Cardiology</i> , 2020, 17, 360-377.	6.1	82
80	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. <i>American Heart Journal</i> , 2021, 235, 104-112.	1.2	82
81	Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 173-176.	4.3	81
82	Inclisiran – New hope in the management of lipid disorders?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 16-27.	0.6	80
83	Alirocumab vs usual lipid-lowering care as addition to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY 4 Dyslipidemia randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	2.2	76
84	Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature. <i>Clinical Therapeutics</i> , 2016, 38, 1696-1709.	1.1	73
85	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 853-864.	1.3	71
86	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 2269-2279.	6.3	70
87	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 649-659.e6.	0.6	70
88	Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1337-1341.	2.2	69
89	“Highest risk” “highest benefit”™ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. <i>European Heart Journal</i> , 2018, 39, 2546-2550.	1.0	69
90	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet</i> , The, 2022, 399, 719-728.	6.3	69

#	ARTICLE	IF	CITATIONS
91	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	6.3	67
92	Beyond Lipid Lowering: What Have We Learned About the Benefits of Statins from the Acute Coronary Syndromes Trials?. <i>American Journal of Cardiology</i> , 2006, 98, S18-S25.	0.7	61
93	Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. <i>Cardiology and Therapy</i> , 2015, 4, 25-38.	1.1	59
94	Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. <i>European Heart Journal</i> , 2006, 27, 2310-2316.	1.0	57
95	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , 2019, 288, 194-202.	0.4	56
96	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016, 6, 19188.	1.6	55
97	Universal screening at age 1â€“2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. <i>Atherosclerosis</i> , 2018, 275, 434-443.	0.4	55
98	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , 2020, 41, 2304-2312.	1.0	54
99	Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. <i>Cardiovascular Research</i> , 2021, 117, 284-291.	1.8	51
100	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 45-51.	0.7	49
101	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.4	47
102	Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 199.	1.1	47
103	Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans. <i>Lipids in Health and Disease</i> , 2017, 16, 192.	1.2	42
104	Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 95-103.	1.2	42
105	Inclisiran for the treatment of dyslipidemia. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 287-294.	1.9	40
106	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. <i>European Heart Journal</i> , 2022, 43, 1715-1727.	1.0	40
107	Epidemiology of familial hypercholesterolaemia: Community and clinical. <i>Atherosclerosis</i> , 2018, 277, 289-297.	0.4	39
108	Low Density Lipoprotein Cholesterolâ€“Lowering Strategies and Population Health. <i>Circulation</i> , 2020, 141, 873-876.	1.6	39

#	ARTICLE	IF	CITATIONS
109	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 868-880.	2.2	38
110	Novel emerging therapies in atherosclerosis targeting lipid metabolism. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 611-622.	1.9	36
111	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 354-363.	2.0	33
112	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 162-171.	1.8	32
113	Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. <i>BMJ Open</i> , 2017, 7, e013255.	0.8	32
114	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32
115	Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1831-1843.	1.2	32
116	Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) <i>Tj ETQq0 0 0 rg07 /Overlook 10 Tf 5</i>	0.7	32
117	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. <i>Atherosclerosis</i> , 2019, 290, 59-65.	0.4	30
118	Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. <i>BMJ Open</i> , 2016, 6, e011805.	0.8	29
119	Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 364-374.	2.2	29
120	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. <i>Current Cardiology Reports</i> , 2015, 17, 109.	1.3	28
121	Prediction of cardiovascular risk in patients with familial hypercholesterolaemia. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017, 3, 274-280.	1.8	28
122	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. <i>Circulation</i> , 2015, 132, 433-440.	1.6	27
123	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019, 18, 149.	2.7	27
124	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). <i>American Journal of Cardiology</i> , 2017, 119, 1352-1358.	0.7	26
125	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 70.	2.7	25
126	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	2.7	22

#	ARTICLE	IF	CITATIONS
127	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. <i>BMJ Open</i> , 2017, 7, e013851.	0.8	21
128	PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?. <i>Heart</i> , 2017, 103, 1670-1679.	1.2	21
129	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	3.1	21
130	Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 447-460.	1.8	21
131	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	0.6	20
132	Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 763-770.	1.9	19
133	Clinical implications and outcomes of the ORION Phase III Trials. <i>Future Cardiology</i> , 2021, 17, 769-777.	0.5	19
134	Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. <i>Atherosclerosis</i> , 2015, 241, 62-68.	0.4	18
135	Coronary Artery Calcium to Improve the Efficiency of Randomized Controlled Trials in Primary Cardiovascular Prevention. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1005-1016.	2.3	18
136	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 325, 46-56.	0.4	18
137	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGAM2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
138	Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , 2016, 111, 163-179.	3.1	17
139	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 119-127.	1.4	17
140	Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 422-429.	0.9	17
141	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. <i>Atherosclerosis Plus</i> , 2021, 43, 24-30.	0.3	17
142	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. <i>Atherosclerosis</i> , 2019, 288, 85-93.	0.4	16
143	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. <i>Diabetes and Metabolism</i> , 2017, 43, 453-459.	1.4	15
144	Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. <i>Journal of the American Heart Association</i> , 2018, 7, e009221.	1.6	14

#	ARTICLE	IF	CITATIONS
145	Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. <i>European Heart Journal</i> , 2021, 42, 253-256.	1.0	14
146	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	1.0	13
147	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 6-16.	2.2	13
148	The year in cardiology: cardiovascular prevention. <i>European Heart Journal</i> , 2020, 41, 1157-1163.	1.0	13
149	Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. <i>Current Opinion in Lipidology</i> , 2020, 31, 182-186.	1.2	13
150	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. <i>Heart</i> , 2018, 104, 1699-1705.	1.2	12
151	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. <i>Atherosclerosis</i> , 2022, 343, 28-50.	0.4	12
152	The evolving role of CETP inhibition: beyond HDL cholesterol. <i>Lancet, The</i> , 2015, 386, 412-414.	6.3	11
153	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.4	11
154	Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 654-663.	0.8	11
155	Familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2020, 31, 111-118.	1.2	11
156	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1663-1674.	0.8	9
157	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , 2020, 42, e6-e8.	1.2	9
158	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.4	9
159	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	1.0	9
160	Time to Benefit. <i>Critical Pathways in Cardiology</i> , 2005, 4, 43-45.	0.2	8
161	Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk. <i>Acta Diabetologica</i> , 2019, 56, 87-96.	1.2	8
162	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e016506.	1.6	8

#	ARTICLE	IF	CITATIONS
163	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , 2021, 322, 77-81.	0.4	8
164	Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 294-301.	1.0	8
165	Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 46-51.	0.4	7
166	Lipids and Lipoproteins in Risk Prediction. <i>Cardiology Clinics</i> , 2018, 36, 213-220.	0.9	7
167	Improving the global care of familial hypercholesterolaemia: Starting the ball rolling. <i>Atherosclerosis</i> , 2018, 277, 230-233.	0.4	7
168	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 286, 40-45.	0.4	7
169	Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. <i>British Journal of Pharmacology</i> , 2021, 178, 2168-2185.	2.7	7
170	Cholesterol Efflux Capacity as a Novel Biomarker for Incident Cardiovascular Events. <i>Circulation Research</i> , 2015, 116, 1646-1648.	2.0	6
171	Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 30-31.	1.4	6
172	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. <i>Atherosclerosis</i> , 2018, 277, 470-476.	0.4	6
173	A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1101-1110.	2.2	6
174	Apabetalone – ÎABET protein inhibition in cardiovascular disease and Type 2 diabetes. <i>Future Cardiology</i> , 2020, 16, 385-395.	0.5	6
175	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ÎADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953.	1.3	6
176	Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 10-13.	1.0	5
177	Familial hypercholesterolaemia: a common disease. <i>European Heart Journal</i> , 2016, 37, 1395-1397.	1.0	5
178	Lp(a) and cardiovascular disease – Has the phoenix finally risen from the ashes?. <i>European Heart Journal</i> , 2019, 40, 2771-2774.	1.0	5
179	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions. <i>Current Cardiology Reports</i> , 2021, 23, 136.	1.3	5
180	American Heart Association – TM's Cholesterol CarePlan as a Smartphone-Delivered Web App for Patients Prescribed Cholesterol-Lowering Medication: Protocol for an Observational Feasibility Study. <i>JMIR Research Protocols</i> , 2019, 8, e9017.	0.5	5

#	ARTICLE	IF	CITATIONS
181	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	1.5	5
182	Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future. <i>Atherosclerosis</i> , 2022, 340, 51-52.	0.4	5
183	New worldwide lipid guidelines. <i>Current Opinion in Cardiology</i> , 2015, 30, 447-453.	0.8	4
184	What imaging techniques should be used in primary versus secondary prevention for further risk stratification?. <i>Atherosclerosis Supplements</i> , 2017, 26, 36-44.	1.2	4
185	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. <i>Atherosclerosis</i> , 2017, 263, 112-118.	0.4	4
186	Time to change the SCORE?. <i>European Heart Journal</i> , 2017, 38, 595-597.	1.0	4
187	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5253-5262.	1.8	4
188	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020, 9, e018189.	1.6	4
189	The power of lipid registries for cardiovascular disease prevention. <i>Current Opinion in Lipidology</i> , 2021, Publish Ahead of Print, 342-348.	1.2	4
190	FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia. <i>Scientific Reports</i> , 2021, 11, 20421.	1.6	4
191	Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. <i>Atherosclerosis Plus</i> , 2022, 49, 20-27.	0.3	4
192	Intensive statin therapy for treating acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1151-1159.	1.9	3
193	Biomarkers, C-reactive proteins and statins in acute coronary syndromes. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 31-33.	1.0	3
194	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment – a clinical appraisal. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1451-1457.	1.2	3
195	Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. <i>American Heart Journal</i> , 2022, 243, 54-65.	1.2	3
196	Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. <i>Current Opinion in Lipidology</i> , 2014, 25, 413-417.	1.2	2
197	Where to now in cardiovascular disease prevention. <i>Atherosclerosis</i> , 2016, 251, 483-489.	0.4	2
198	Lipoprotein(a), the rediscovered risk factor, or how to get “back to the future”. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 147-151.	0.7	2

#	ARTICLE	IF	CITATIONS
199	Non-statin interventions in the prevention of cardiovascular events: Sex-based meta-analysis. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 228-232.	1.6	2
200	TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial. <i>Atherosclerosis</i> , 2021, 322, 8-14.	0.4	2
201	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGram2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4472.	1.0	2
202	Will genetic studies deliver the next generation of cardioprotective therapies?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 489-491.	0.8	1
203	Response by Vallejo-Vaz et al to Letters Regarding Article, a€œLow-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Upâ€ Circulation, 2018, 137, 2419-2420.	1.6	1
204	Hypercholesterolemia Among Prematureâ€Infarcts. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2451-2453.	1.2	1
205	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. <i>Biomarker Insights</i> , 2022, 17, 117727192110667.	1.0	1
206	Author reply: Which risk engines are best to assess CVD risk in diabetes?. <i>Nature Reviews Endocrinology</i> , 2010, 6, 116-116.	4.3	0
207	Diabetic microvascular triopathy, smoking, and risk of cardiovascular events â€ Author's reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 888-889.	5.5	0
208	The need for a new classification of cholesterol lowering therapies. <i>Current Medical Research and Opinion</i> , 2017, 33, 67-69.	0.9	0
209	The year in cardiology: cardiovascular prevention /The year in cardiology 2019. <i>Revista Romana De Cardiologie</i> , 2020, 30, 20-29.	0.0	0
210	Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records. <i>JMIR Research Protocols</i> , 2020, 9, e17548.	0.5	0
211	Abstract 14248: Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials. <i>Circulation</i> , 2020, 142, .	1.6	0
212	Abstract 11033: Efficacy and Safety of Inclisiran by Baseline Glycemic Status: A Post Hoc Pooled Analysis of the ORION-10 and ORION-11 Phase III Randomized Controlled Trials. <i>Circulation</i> , 2021, 144, .	1.6	0
213	Abstract 11143: Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials. <i>Circulation</i> , 2021, 144, .	1.6	0
214	459â€fEvaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0